Summary
Androgen deprivation therapy is the cornerstone treatment for metastatic prostate cancer. It can be done either surgically or medically. Luteinizing hormone-releasing hormone agonists and antagonist are the most effective drugs, with different side effects and modes of action, but no clear efficacy differences. Adding a non-steroidal antiandrogen adds a marginal benefit but also significant side effects and costs. Non-steroidal antiandrogens should not be used as monotherapy. In most patients with metastases, immediate castration is the standard of care. The intermittent modality is apparently non-inferior to the continuous one, with some other benefits. Upfront chemotherapy added to castration should be considered as the new standard of care in many metastatic patients. Castration leads to many adverse effects, some potentially life-threatening such as cardiovascular side effects.
Journal Section:
Review Article
References
1.
Mottet N, Bellmunt J, Briers E, van den Bergh RCN, Bolla M, van Casteren NJ, Cornford P, Culine S, Joniau S, Lam T, Mason MD, Matveev V, van der Poel H, van der Kwast TH, Rouviere O, Wiegel T: Guidelines on prostate cancer, 2015 (cited 2015 Aug 2); http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LRV2-2015.pdf.
2.
Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9-12.
[PubMed]
3.
Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI: Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56:1021-1024.
[PubMed]
4.
Pickles T, Hamm J, Morris WJ, Schreiber WE, Tyldesley S: Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter? BJU Int 2012;110:E500-507.
[PubMed]
5.
Mcleod DG: Hormonal therapy: historical perspective to future directions. Urology 2003;61:3-7.
[PubMed]
6.
Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, et al.: Single-therapy androgen suppression in men with advanced prostate cancer. A systematic review and meta-analysis. Ann Intern Med 2000;132:566-577.
[PubMed]
7.
Scherr DS, Pitts WR Jr: The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003;170:1703-1708.
[PubMed]
8.
No authors listed: Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-Operative Urological Research Group. Surg Gynecol Obstet 1967;124:1011-1017.
[PubMed]
9.
Byar DP, Corle DK: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr Publ Natl Cancer Inst 1988;165-170.
[PubMed]
10.
Klotz L, McNeill I, Fleshner N: A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999;161:169-172.
[PubMed]
11.
Hedlund PO, Damber J-E, Hagerman I, Haukaas S, Henriksson P, Iversen P, et al.: Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42:220-229.
[PubMed]
12.
Shahinian VB, Kuo Y, Freeman JL, Orihuela E, Goodwin JS: Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005;103:1615-1624.
[PubMed]
13.
Van Poppel H, Klotz L: Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 2012;19:594-601.
[PubMed]
14.
21320_plenaxis_lbl.pdf (cited 2015 Aug 9); www.accessdata.fda.gov/drugsatfda_docs/label/2003/21320_plenaxis_lbl.pdf
15.
Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, et al.: A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 2011;186:889-897.
[PubMed]
16.
Rossi D, Cornu J-N, Roupret M: De l'estrogénothérapie aux agonistes de la LHRH. Prog Urol 2007;17:287-290.
[PubMed]
17.
Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-244.
[PubMed]
18.
Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS: Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol Off J Am Soc Clin Oncol 2004;22:2546-2553.
[PubMed]
19.
Glass TR, Tangen CM, Crawford ED, Thompson I: Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003;169:164-169.
[PubMed]
20.
Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al.: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24:3984-3990.
[PubMed]
21.
James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al.: Survival with newly diagnosed metastatic prostate cancer in the ‘docetaxel era': data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 2015;67:1028-1038.
[PubMed]
22.
Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, et al.: Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61:11-25.
[PubMed]
23.
Nair B, Wilt T, MacDonald R, Rutks I: Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002;CD003506.
[PubMed]
24.
Bayoumi AM, Brown AD, Garber AM: Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000;92:1731-1739.
[PubMed]
25.
Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, et al.: Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer (online); Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2014 (cited 2015 Aug 13); onlinelibrary.wiley.com/doi/ 10.1002/14651858.CD009266.pub2/abstract.
26.
No authors listed: Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Prostate Cancer Trialists' Collaborative Group. Lancet Lond Engl 2000;355:1491-1498.
[PubMed]
27.
Collette L, Studer UE, Schröder FH, Denis LJ, Sylvester RJ: Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. Prostate 2001;48:29-39.
[PubMed]
28.
Niraula S, Le LW, Tannock IF: Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol 2013;31:2029-2036.
[PubMed]
29.
Abrahamsson P-A: Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49-59.
[PubMed]
30.
Hussain M, Tangen CM, Berry DL, et al.: Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368:1314-1325.
[PubMed]
31.
Higano C, Shields A, Wood N, et al.: Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004;64:1182-1186.
[PubMed]
32.
Gravis G, Fizazi K, Joly F, et al.: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomized, open-label, phase 3 trial. Lancet Oncol 2013;14:149-158.
[PubMed]
33.
Sweeney CJ, Chen YH, Carducci M, et al.: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737-746.
[PubMed]
34.
James, N Sydes M, Mason M, et al.: Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first survival results from STAMPEDE. J Clin Oncol 2015;33(suppl 15):abstr 5001.
35.
Smith TJ, Bohlke K, Lyman GH, et al.: Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015;33:3199-3212.
[PubMed]
36.
Ahmadi H, Daneshmand S: Androgen deprivation therapy: evidence-based management of side effects. BJU Int 2013;111:543-548.
[PubMed]
37.
Braga-Basaria M, Dobs AS, Muller DC, et al.: Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24:3979-3983.
[PubMed]
38.
Keating NL, O'Malley JO, Freedland SJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39-46.
[PubMed]
39.
Nguyen PL, Chen MH, Beckman JA, et al.: Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys 2012;82:1411-1416.
[PubMed]
40.
Tsai HK, D'Amico AV, Sadetsky N, et al.: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516-1524.
[PubMed]
41.
Calais da Silva FEC, Bono AV, Whelan P, et al.: Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomized phase 3 study of the South European Uroncological Group. Eur Urol 2009;55:1269-1277.
[PubMed]
42.
Salonen AJ, Taari K, Ala-Opas M, et al.: The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 2012;187:2074-2081.
[PubMed]
43.
Langenhuijsen JF, Badhauser D, Schaaf B, et al.: Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol 2013;31:549-556.
[PubMed]
44.
Mottet N, Van Damme J, Loulidi S, et al.: Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. BJU Int 2012;110:1262-1269.
[PubMed]
45.
De Leval J, Boca P, Yousef E, et al.: Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1:163-171.
[PubMed]
46.
Gravis G, Boher J-M, Joly F, et al.: Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): long-term analysis of the GETUG-AFU 15 phase III trial. J Clin Oncol 2015;33(suppl 7):abstr 140.
[PubMed]
© 2015 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.
